Colorectal Cancer – Global Drug Forecast and Market Analysis to 2028

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

 

Colorectal cancer (CRC) occurs in the large intestine or large bowel. It is the third most common cancer globally and is one of the most common causes of cancer deaths in the world. Early stage CRC is commonly treated with surgery, while metastatic colorectal cancer (mCRC) treatment is dominated by fluorouracil chemotherapy regimens in combination with angiogenesis inhibitors, primarily Roche’s Avastin, and epidermal growth factor receptor (EGFR) inhibitors.

GlobalData valued the CRC market at $7.6B in 2018. This market is defined as sales of generic chemotherapy and major branded drugs commonly prescribed for CRC patients across the 8MM. GlobalData expects the market to increase to $10.7B in 2028 at a Compound Annual Growth Rate (CAGR) of 3.5%. This global growth is driven by the anticipated approval and launch of 9 pipeline therapies and label expansion of other agents, but will likely be tempered by marked generic erosion of the majority of the currently marketed branded therapies available in 2018.

KEY QUESTIONS ANSWERED

  • Nine late-stage pipeline agents are going to enter the mCRC market from 2018 onwards. What impact will these agents have on the market? Which of these drugs will have the highest peak sales, and why?
  • What are the current unmet needs in mCRC and which pipeline agents are positioned to counter these unmet needs? What are the opportunities for R&D?
  • What is the market outlook in the 8MM from 2018-2028? Considering major patent expiries, launch of new premium priced agents and expected label expansions.
  • What are the main corporate trends? Who are the current and future players?

Scope

Overview of metastatic colorectal cancer including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.

Topline metastatic colorectal cancer market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.

Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting metastatic colorectal cancer therapeutics sales in the 8MM.

Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.

Analysis of the current and future market competition in the global metastatic colorectal cancer therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key Highlights

The main drivers of growth include the anticipated approval and launch of 9 pipeline therapies, in addition to label expansions of currently marketed therapies across the 8MM during the forecast period.

The main barriers to growth in the 8MM include the patent expiry of major brands and the high price of premium priced therapeutics entering the market.

The rapidly growing aging population will lead to an increase in the CRC incident case in the markets covered in this report. Overall, the diagnosed incident cases of CRC across the 8MM are expected to increase by an Annual Growth Rate (AGR) of 1.9% from 2018–2028.

GlobalData found that there is a large unmet need for the identification of new targets and biomarkers to guarantee the optimal integration of current and future therapies into the treatment paradigm and to improve patient outcomes.

Reasons to Buy

The report will enable you to:

Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.

Develop business strategies by understanding the trends shaping and driving the global metastatic colorectal cancer therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global metastatic colorectal cancer cancer market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Track drug sales in the global metastatic colorectal cancer therapeutics market from 2018-2028.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.


Roche
Amgen
Eli Lilly
Bayer
Bristol-Myers Squibb
Merck KGaA
Merck & Co
Novartis
Pfizer
Sanofi
Taiho
Boston Biomedical
Isofol
Ono Pharmaceuticals

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Colorectal Cancer: Executive Summary

2.1 CRC Market is Expected to Grow to $10.7B in 2028

2.2 Avastin to Remain Leader despiteCompetition from Novel Mechanisms of Action

2.3 Unmet Need Will Remain for the Identification of New Targets and Biomarkers of Response

2.4 CRC Pipeline Moving Towards Precision Medicine in Both the Early and Metastatic Setting

2.5 What Do Physicians Think?

3 Introduction

3.1 Catalyst

3.2 Related Reports

3.3 Upcoming Related Reports

4 Disease Overview

4.1 Etiology and Pathophysiology

4.1.1 Etiology

4.1.2 Pathophysiology

4.2 Classification or Staging Systems for CRC

4.3 Clinical Presentation

5 Epidemiology

5.1 Disease Background

5.2 Risk Factors and Comorbidities

5.3 Global and Historical Trends

5.4 Forecast Methodology

5.4.1 Sources Used

5.4.2 Sources Not Used

5.4.3 Forecast Assumptions and Methods

5.5 Epidemiological Forecast for CRC

5.5.1 Diagnosed Incident Cases of CRC

5.5.2 Age-Specific Diagnosed Incident Cases of CRC

5.5.3 Sex-Specific Diagnosed Incident Cases of CRC

5.5.4 Diagnosed Incident Cases of CRC by Stage at Diagnosis

5.5.5 Diagnosed Incident Cases of CRC by Molecular Markers

5.5.6 Diagnosed Incident Cases of CRC by Population with Curable Synchronous Liver Metastasis

5.5.7 Diagnosed Incident Cases of CRC by Sidedness

5.5.8 Five-Year Diagnosed Prevalent Cases of CRC

5.5.9 All-Time Diagnosed Prevalent Cases of CRC

5.6 Discussion

5.6.1 Epidemiological Forecast Insight

5.6.2 Limitations of the Analysis

5.6.3 Strengths of the Analysis

6 Disease Management

6.1 Screening and Diagnosis

6.1.1 Summary

6.1.2 Fecal Testing

6.1.3 Colonoscopy

6.1.4 Flexible Sigmoidoscopy

6.1.5 Computed Tomography Colonography

6.1.6 Recent and Emerging Advances

6.2 Treatment Guidelines

6.3 Clinical Practice

6.4 US

6.4.1 Screening

6.4.2 Treatment Pathways

6.4.3 Biomarker Testing

6.5 5EU

6.5.1 Screening

6.5.2 Treatment Pathways

6.5.3 Biomarker Testing

6.6 Japan

6.6.1 Screening

6.6.2 Treatment Pathways

6.6.3 Biomarker Testing

6.7 China (Urban)

6.7.1 Screening

6.7.2 Treatment Pathways

6.7.3 Biomarker Testing

7 Competitive Assessment

7.1 Overview

8 Unmet Needs and Opportunity Assessment

8.1 Overview

8.2 Improved Treatments for Patients with KRAS/NRAS Mutations

8.3 Continued Improvement in Precision Medicine

8.4 Reducing Age for Routine Screening

8.5 Overcoming Resistance to Angiogenesis and EGFR-Targeting Therapy

9 Pipeline Assessment

9.1 Overview

9.2 Promising Drugs in Clinical Development

10 Current and Future Players

10.1 Overview

10.2 Trends in Corporate Strategy

10.3 Roche

10.4 Amgen

10.5 Eli Lilly

10.6 Bayer

10.7 Bristol-Myers Squibb

10.8 Merck KGaA

10.9 Merck & Co.

10.10 Novartis

10.11 Pfizer

10.12 Sanofi

10.13 Taiho

11 Market Outlook

11.1 Global Markets

11.1.1 Forecast

11.1.2 Drivers and Barriers – Global Issues

11.2 US

11.2.1 Forecast

11.2.2 Key Events

11.2.3 Drivers and Barriers

11.3 5EU

11.3.1 Forecast

11.3.2 Key Events

11.3.3 Drivers and Barriers

11.4 Japan

11.4.1 Forecast

11.4.2 Key Events

11.4.3 Drivers and Barriers

11.5 China

11.5.1 Forecast

11.5.2 Key Events

11.5.3 Drivers and Barriers

12 Appendix

12.1 Bibliography

12.2 Abbreviations

12.3 Methodology

12.3.1 Forecasting Methodology

12.3.2 Diagnosed Patients

12.3.3 Drugs Included in Each Therapeutic Class

12.3.4 Launch and Patent Expiry Dates

12.3.5 General Pricing Assumptions

12.3.6 Individual Drug Assumptions for Marketed Products

12.3.7 Individual Drug Assumptions for Off-Label Products

12.3.8 Generic Erosion

12.3.9 Pricing of Pipeline Agents

12.4 Primary Research – Key Opinion Leaders Interviewed for This Report

12.5 Primary Research – Prescriber Survey

12.6 About the Authors

12.6.1 Analyst

12.6.2 Therapy Area Director

12.6.3 Epidemiologist

12.6.4 Epidemiology Reviewers

12.6.5 Global Director of Therapy Analysis and Epidemiology

12.6.6 Global Head and EVP of Healthcare Operations and Strategy

12.7 About GlobalData

12.8 Contact Us

12.9 Disclaimer

Table

Table 1: Colorectal Cancer: Key Metrics in the 8MM

Table 2: 8MM,TNM Staging and Classification for CRC

Table 3: Risk Factors and Comorbid Conditions Associated with CRC

Table 4: 8MM, Diagnosed Incident Cases of CRC by Molecular Markers, N, Both Sexes, Ages ≥18 Years, 2018

Table 5: CRC Disease Management Across the 8MM

Table 6: Treatment Guidelines for CRC

Table 7: Leading Treatments for mCRC, 2018

Table 8: Roche’s CRC Portfolio Assessment, 2020

Table 9: Amgen’s CRC Portfolio Assessment, 2020

Table 10: Eli Lilly’s CRC Portfolio Assessment, 2020

Table 11: Bayer’s CRC Disease Portfolio Assessment, 2020

Table 12: Bristol-Myers Squibb‘s CRC Portfolio Assessment, 2020

Table 13: Merck KGA’s CRC Disease Portfolio Assessment, 2020

Table 14: Merck & Co.’s CRC Disease Portfolio Assessment, 2020

Table 15: Novartis’s CRC Disease Portfolio Assessment, 2020

Table 16: Pfizer’s CRC Portfolio Assessment, 2020

Table 17: Sanofi’s CRC Portfolio Assessment, 2020

Table 18: Taiho’s CRC Disease Portfolio Assessment, 2020

Table 19: CRC Market – Global Drivers and Barriers, 2018–2028

Table 20: Key Events Impacting Sales for CRC in the US, 2018–2028

Table 21: CRC Drivers and Barriers in the US, 2018–2028

Table 22: Key Events Impacting Sales for CRC in the 5EU, 2018–2028

Table 23: CRC – Drivers and Barriers in the 5EU, 2018–2028

Table 24: Key Events Impacting Sales for CRC in Japan, 2018–2028

Table 25: CRC – Global Drivers and Barriers in Japan, 2018–2028

Table 26: Key Events Impacting Sales for CRC in China, 2018–2028

Table 27: CRC – Global Drivers and Barriers in China, 2018–2028

Table 28: Key Historical and Projected Launch Dates for CRC

Table 29: Key Historical and Projected Patent Expiry Dates for mCRC

Table 30: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

Figures

Figure 1: Global Sales Forecast by Country for CRC in 2018 and 2028

Figure 2: Analysis of the Company Portfolio Gap in CRC During the Forecast Period

Figure 3: Competitive Assessment of the Late-Stage CRC Pipeline Agents

Figure 4: Diagram of the Cancers of the Colon and Rectum

Figure 5: 8MM, Diagnosed Incidence of CRC (Cases per 100,000 Population), Men, Ages ≥18 Years, 2018–2028

Figure 6: 8MM, Diagnosed Incidence of CRC (Cases per 100,000 Population), Women, Ages ≥18 Years, 2018–2028

Figure 7: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of CRC

Figure 8: 8MM, Sources Used to Forecast the Five-Year Diagnosed and Diagnosed Prevalent Cases of CRC

Figure 9: 8MM, Sources Used and Not Used to Forecast the Diagnosed Incident Cases of CRC by Stage at Diagnosis

Figure 10: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of CRC by Molecular Markers

Figure 11: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of CRC by Population with Curable Synchronous Liver Metastases

Figure 12: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of CRC by Sidedness

Figure 13: 8MM, Diagnosed Incident Cases of CRC, N, Both Sexes, ≥18 Years, 2018

Figure 14: 8MM, Age-Specific Diagnosed Incident Cases of CRC, N, Both Sexes, Ages ≥18 Years, 2018

Figure 15: 8MM, Sex-Specific Diagnosed Incident Cases of CRC, N, Ages ≥18 Years, 2018

Figure 16: 8MM, Diagnosed Incident Cases of CRC by Stage at Diagnosis, N, Both Sexes, Ages ≥18 Years, 2018

Figure 17: 8MM, Diagnosed Incident Cases of CRC by Population with Curable Synchronous Liver Metastasis, N, Both Sexes, Ages ≥18 Years, 2018

Figure 18: 8MM, Diagnosed Incident Cases of CRC by Sidedness, N, Both Sexes, Ages ≥18 Years, 2018

Figure 19: 8MM, Five-Year Diagnosed Prevalent Cases of CRC, N, Both Sexes, Ages ≥18 Years, 2018

Figure 20: 8MM, Diagnosed Prevalent Cases of CRC, N, Both Sexes, Ages ≥18 Years, 2018

Figure 21: Unmet Needs and Opportunities in CRC

Figure 22: Overview of the Development Pipeline in CRC

Figure 23: Key Phase II/III Trials for Promising CRC Pipeline Agents

Figure 24: Competitive Assessment of the Late-Stage CRC Pipeline Agents

Figure 25: Analysis of the Company Portfolio Gap in mCRC During the Forecast Period

Figure 26: 8MM, Sales Forecast by Country for CRC in 2018 and 2028

Figure 27: 8MM, Sales Forecast by Drug Class for CRC in 2018 and 2028

Figure 28: Sales Forecast by Class for CRC in the US, 2018 and 2028

Figure 29: Sales Forecast by Class for CRC in the EU, 2018 and 2028

Figure 30: Sales Forecast by Class for CRC in Japan in 2018 and 2028

Figure 31: Sales Forecast by Class for CRC in China in 2018 and 2028

Frequently asked questions

Colorectal Cancer – Global Drug Forecast and Market Analysis to 2028 thematic reports
Currency USD
$10,995

Can be used by individual purchaser only

$32,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Colorectal Cancer – Global Drug Forecast and Market Analysis to 2028 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Colorectal Cancer – Global Drug Forecast and Market Analysis to 2028 in real time.

  • Access a live Colorectal Cancer – Global Drug Forecast and Market Analysis to 2028 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.